Dublin, April 21, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/rsmwfn/complete_201516) has announced the addition of the "Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report" report to their offering.
Stem cell research and experimentation have been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their unspecialized nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in reversal and treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Conditions such as Huntington's disease, Parkinson's disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage.
Traditionally, scientists have worked with both embryonic and adult stem cells for research tools, as well as for cellular therapy. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral, and spiritual controversy surrounding their use. Although some adult stem cells do have differentiation capacity, it is often limited in nature, which results in fewer options for use. Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics.
Key Topics Covered:
1. EXECUTIVE SUMMARY
2. PURPOSE OF REPORT
3. TARGET DEMOGRAPHIC
4. SCOPE OF iPSC MARKET
5. RESEARCH METHODOLOGY
6. TECHNICAL OVERVIEW OF iPSCs
7. TIMELINE OF KEY iPSC EVENTS
8. LEVELS OF REPAIR INDUCIBLE WITH iPSCs
9. iPSC INDUSTRY CONDITIONS
10. RESEARCH APPLICATIONS FOR iPSCs
11. CHARACTERIZATION OF iPSC RESEARCH ADVANCES
12. COMPANIES SELLING iPSC RESEARCH PRODUCTS
13. iPSC RESEARCH PRODUCTS MARKET
14. COMPANIES DEVELOPING iPSC THERAPIES
15. STRATEGIC COLLABORATIONS FOR DEVELOPMENT OF iPSC PRODUCTS
16. MARKET SIZE DETERMINATIONS & PROJECTIONS
17. MARKET TREND ANALYSIS
18. MARKETING ANALYSIS: PRICE-PER-CLICK FOR iPSC-RELATED SEARCH TERMS
19. SCIENTIST PANEL: DETAILED END-USER SURVEY
20. STRATEGIES FOR ACCESSING THE iPSC MARKETPLACE
21. CONCLUSIONS
Companies Mentioned
- ArunA Biomedical
- California Institute for Regenerative Medicine (CIRM)
- CeeTox and Cellular Dynamics International (Owned by Fujifilm Holdings)
- Cellular Dynamics International, Owned by FujiFilm Holdings (Industrial-Scale Production of iPSCs)
- EMD Millipore
- Fate Therapeutic
- Kyoto University
- Life Technologies, Owned by Thermo Fisher Scientific
- Lonza Group AG
- Ocata Therapeutics (Previously Advanced Cell Technology)
- RIKEN Center
- Roslin Cells, Ltd.
- Sigma Aldrich
- ViaCyte
- iPerian
For more information visit http://www.researchandmarkets.com/research/rsmwfn/complete_201516
Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report
| Source: Research and Markets